English | 简体中文 | 繁體中文 | 한국어
 English Press Releases
 Pharma & Biotech Clinical Trials
Novotech Receives CRO Leadership Award for Exceeding Customer Expectations
Jun 23, 2022 08:00 HKT
SINGAPORE ANNUAL MEETING: DIA and CoRE Gathering Key Healthcare Experts in Neutral Forum to Discuss Regulatory News and Drug Development
Jun 15, 2022 08:30 HKT
Novotech's APAC and USA Leadership Teams at BIO 2022
Jun 14, 2022 22:00 HKT
Novotech Sponsors Endpoints ASCO 2022 Expert Panel on Accelerating Oncology Clinical Trials in China
Jun 06, 2022 18:00 HKT
Novotech Sponsors Pre-ASCO China Summit Panels on Early Phase Oncology Trials, Regulatory Strategy for China and US
Jun 02, 2022 18:00 HKT
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory
May 12, 2022 15:00 HKT
Novotech Sponsors Pre-ASCO China Summit: Go/No Go Decisions Based on Early Phase Oncology Trials
May 12, 2022 06:00 HKT
Novotech Acquires US CRO NCGS, Expands Global Expertise
May 05, 2022 09:00 HKT
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 - Best Contract Research Organization in APAC
Apr 19, 2022 10:00 HKT
Avance Clinical Announces New Office Opening in Melbourne
Mar 31, 2022 15:00 HKT
Avance Clinical Announces New Office Opening in Sydney
Mar 02, 2022 15:00 HKT
Therapeutic Goods Administration of Australia Authorizes Moderna's Covid-19 Vaccine in Children (6-11 Years)
Feb 17, 2022 10:45 HKT
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries
Feb 16, 2022 07:00 HKT
Novotech Recognized as Top 10 CRO in CenterWatch Global Site Relationship Benchmarking Report
Feb 09, 2022 15:00 HKT
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022
Jan 18, 2022 13:00 HKT
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
Jan 12, 2022 09:25 HKT
B-cell lymphoma clinical trials now open on the TrialWire Platform
Jan 05, 2022 17:10 HKT
Autism clinical trials now open on the TrialWire Platform
Jan 05, 2022 17:00 HKT
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
Jan 04, 2022 10:10 HKT
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Nov 22, 2021 10:40 HKT
Next >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: